Walker K J, Bouzubar N, Robertson J, Ellis I O, Elston C W, Blamey R W, Wilson D W, Griffiths K, Nicholson R I
Tenovus Institute for Cancer Research, University of Wales College of Medicine, Cardiff.
Cancer Res. 1988 Nov 15;48(22):6517-22.
An immunocytochemical assay for the measurement of estrogen receptor (ER-ICA; Abbott Diagnostics) has been evaluated in 163 human breast carcinomas. Specific binding was observed in the nuclei of 111 of 163 (68%) tumors. An excellent correlation was observed between the ER-ICA and the estrogen receptor enzyme immunoassay. A significant relationship was observed between ER-ICA status and percentage of ER-ICA negative cells, histological grade of malignancy, and mitotic activity of the tumors. A significant correlation was also observed between ER-ICA status and age at mastectomy with 50% of patients with ER-ICA positive breast tumors presenting with their disease over 60 years of age. No association was observed with either tumor size or patient nodal status. Examination of the proportion of negative cells within tumors revealed a trend for the acquisition of poor prognostic features to be associated with an increase in the negative cell population. Data on the recurrence free interval of these patients showed a significant recurrence free advantage in ER-ICA positive patients, particularly those whose tumors contained low numbers of negative cells.
一种用于测量雌激素受体的免疫细胞化学检测法（ER-ICA；雅培诊断公司）已在163例人类乳腺癌中进行了评估。在163例肿瘤中的111例（68%）肿瘤细胞核中观察到特异性结合。ER-ICA与雌激素受体酶免疫测定法之间观察到极好的相关性。ER-ICA状态与ER-ICA阴性细胞百分比、恶性组织学分级以及肿瘤的有丝分裂活性之间观察到显著关系。ER-ICA状态与乳房切除术时的年龄之间也观察到显著相关性，50%的ER-ICA阳性乳腺癌患者在60岁以上出现疾病。未观察到与肿瘤大小或患者淋巴结状态有关联。对肿瘤内阴性细胞比例的检查显示，获得不良预后特征的趋势与阴性细胞群体增加有关。这些患者无复发生存期的数据显示，ER-ICA阳性患者，尤其是那些肿瘤中阴性细胞数量较少的患者，具有显著的无复发优势。
